Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al., editors. The WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC; 2017.
   Google Scholar
• Li Y, Wang Y, Wang Z, et al. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39(1):8–13.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Sukswai N, Lyapichev K, Khoury JD, et al. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020;52(1):53–67.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
   PubMed Web of Science ®Google Scholar
• Shipp MA. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–2380.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14(6):460–467.e2.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828–1837.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118(5):1350–1358.
   PubMed Web of Science ®Google Scholar
• Staiger AM, Ziepert M, Horn H, et al. Clinical Impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515–2526.
   PubMed Web of Science ®Google Scholar
• Staiger AM, Altenbuchinger M, Ziepert M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34(2):543–552.
   PubMed Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–1217.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Abramson JS. Hitting back at lymphoma: how do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Cancer. 2019;125(18):3111–3120.
   PubMed Web of Science ®Google Scholar
• Tian XP, Huang WJ, Huang HQ, et al. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. Leukemia. 2019;33(10):2454–2465.
   PubMed Web of Science ®Google Scholar
• Takashima Y, Kawaguchi A, Iwadate Y, et al. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS One. 2019;14(1):e0210400.
   PubMed Web of Science ®Google Scholar
• Hershkovitz-Rokah O, Geva P, Salmon-Divon M, et al. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget. 2018;9(8):7928–7941.
   PubMedGoogle Scholar
• Larrabeiti-Etxebarria A, Lopez-Santillan M, Santos-Zorrozua B, et al. Systematic review of the potential of microRNAs in diffuse large B cell lymphoma. Cancers (Basel). 2019;11(2):144.
   Web of Science ®Google Scholar
• Due H, Schonherz AA, Ryo L, et al. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Adv. 2019;3(7):1185–1196.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–1259.
   PubMed Web of Science ®Google Scholar
• Simon N, Friedman J, Hastie T, et al. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13.
   PubMed Web of Science ®Google Scholar
• Altenbuchinger M, Rehberg T, Zacharias HU, et al. Reference point insensitive molecular data analysis. Bioinformatics. 2017;33(2):219–226.
   PubMed Web of Science ®Google Scholar
• Horn H, Staiger AM, Vohringer M, et al. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. Am J Surg Pathol. 2015;39(1):61–66.
   PubMed Web of Science ®Google Scholar
• Sole C, Arnaiz E, Lawrie CH. MicroRNAs as biomarkers of B-cell lymphoma. Biomark Insights. 2018;13:1177271918806840.
   Web of Science ®Google Scholar
• Lindahl LM, Besenbacher S, Rittig AH, et al. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood. 2018;131(7):759–770.
   PubMed Web of Science ®Google Scholar
• Yang C, Dou R, Yin T, et al. MiRNA-106b-5p in human cancers: diverse functions and promising biomarker. Biomed Pharmacother. 2020;127:110211.
   PubMed Web of Science ®Google Scholar
• Kovaleva V, Mora R, Park YJ, et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 2012;72(7):1763–1772.
   PubMed Web of Science ®Google Scholar
• Yuan WX, Gui YX, Na WN, et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett. 2016;11(1):423–432.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Jiang LH, Sun DW, et al. The role of miR-130a in cancer. Breast Cancer. 2017;24(4):521–527.
   PubMed Web of Science ®Google Scholar
• Tong L, Han WZ, Wang JL, et al. MicroRNA-365 inhibits the progression of lung adenocarcinoma through targeting ETS1 and inactivating AKT/mTOR pathway. Eur Rev Med Pharmacol Sci. 2020;24(9):4836–4845.
   PubMed Web of Science ®Google Scholar
• Guo T, Wang J, Cheng G, et al. miR-590-5p may regulate colorectal cancer cell viability and migration by targeting PDCD4. Exp Ther Med. 2020;20(5):55.
   PubMed Web of Science ®Google Scholar
• Xie J, Tan ZH, Tang X, et al. MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis. World J Gasteroenterol. 2014;20(46):17439–17447.
   PubMed Web of Science ®Google Scholar
• Sun D, Wang X, Sui G, et al. Downregulation of miR-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins. Int J Oncol. 2018;52(5):1491–1503.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Tian Q, Guan L, et al. The dual role of miR-186 in cancers: oncomir battling with tumor suppressor miRNA. Front Oncol. 2020;10:233.
   PubMed Web of Science ®Google Scholar